Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/308% below fair value
$5.84+0.32 (+5.80%)
Close on Nov 13, 2026Market cap $759.10MP/E –Yield –
Cytek Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cytek Biosciences's ebitda for the twelve months ending Sep 30, 2026 was -$36.00M. For fiscal 2025 it was -$32.81M. The highest annual figure on record is $14.26M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.81M | – |
| FY2024 | Dec 31, 2024 | -$13.31M | – |
| FY2023 | Dec 31, 2023 | -$21.80M | -3268.2% |
| FY2022 | Dec 31, 2022 | $688.00K | -93.4% |
| FY2021 | Dec 31, 2021 | $10.40M | -27.1% |
| FY2020 | Dec 31, 2020 | $14.26M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.31M | – |
| Q2 FY2026 | Jun 30, 2026 | -$9.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.70M | -176.4% |
| Q3 FY2025 | Sep 30, 2025 | -$7.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.10M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.84M | +224.0% |
| Q3 FY2024 | Sep 30, 2024 | -$2.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.04M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.49M | +76.8% |
| Q3 FY2023 | Sep 30, 2023 | -$4.65M | -424.9% |
| Q2 FY2023 | Jun 30, 2023 | -$7.48M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.16M | – |
| Q4 FY2022 | Dec 31, 2022 | $845.00K | -57.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.43M | -53.6% |
| Q2 FY2022 | Jun 30, 2022 | -$26.00K | -100.6% |
| Q1 FY2022 | Mar 31, 2022 | -$1.56M | -220.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.00M | -75.1% |
| Q3 FY2021 | Sep 30, 2021 | $3.09M | -55.2% |
| Q2 FY2021 | Jun 30, 2021 | $4.01M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.30M | – |
| Q4 FY2020 | Dec 31, 2020 | $8.03M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.89M | – |
See a number that looks wrong?